Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2801
Franklin Wireless
FKWL
$26M
| $524K | ﹤0.01% |
125,400
+27,000
| +27% | +$123K |
2021 Q2
16 quarters
|
|
2802
ClearPoint Neuro
CLPT
$320M
| $524K | ﹤0.01% |
43,900
-7,100
| -14% | -$89.4K |
2025 Q1
1 quarter
|
|
2803
UroGen Pharma
URGN
$1.8B
| $523K | ﹤0.01% |
38,200
-52,400
| -58% | -$503K |
2024 Q4
2 quarters
|
|
2804
Dimensional International Core Equity 2 ETF
DFIC
$15B
| $522K | ﹤0.01% |
16,800
+1,800
| +12% | +$52.7K |
2025 Q1
1 quarter
|
|
2805
Hayward Holdings
HAYW
$2.41B
| $522K | ﹤0.01% |
37,847
-508,300
| -93% | -$6.85M |
2024 Q4
2 quarters
|
|
2806
Ranpak Holdings
PACK
$318M
| $522K | ﹤0.01% |
+146,100
| New | +$542K |
2025 Q2
0 quarters
|
|
2807
MetroCity Bankshares
MCBS
$984M
| $522K | ﹤0.01% |
+18,249
| New | +$506K |
2025 Q2
0 quarters
|
|
2808
iShares MSCI Mexico ETF
EWW
$1.5B
| $521K | ﹤0.01% |
+8,598
| New | +$495K |
2025 Q2
0 quarters
|
|
|
GOCO
2809
DELISTED
GoHealth
GOCO
| $518K | ﹤0.01% |
93,278
+32,900
| +54% | +$260K |
2022 Q1
13 quarters
|
|
2810
iShares Global Tech ETF
IXN
$9.85B
| $517K | ﹤0.01% |
5,600
-2,200
| -28% | -$178K |
2024 Q4
2 quarters
|
|
2811
Invesco S&P 500 GARP ETF
SPGP
$2.1B
| $517K | ﹤0.01% |
4,800
-19,800
| -80% | -$1.97M |
2024 Q4
2 quarters
|
|
2812
iShares Expanded Tech Sector ETF
IGM
$11.6B
| $517K | ﹤0.01% |
4,600
-5,900
| -56% | -$580K |
2024 Q3
3 quarters
|
|
2813
Eledon Pharmaceuticals
ELDN
$202M
| $517K | ﹤0.01% |
190,673
+67,900
| +55% | +$204K |
2015 Q4
38 quarters
|
|
2814
Finward Bancorp
FNWD
$178M
| $516K | ﹤0.01% |
18,700
+1,700
| +10% | +$50.2K |
2023 Q4
6 quarters
|
|
2815
Live Ventures
LIVE
$23.5M
| $516K | ﹤0.01% |
29,699
-2,000
| -6% | -$29.2K |
2019 Q3
23 quarters
|
|
2816
Red Robin
RRGB
$163M
| $514K | ﹤0.01% |
88,857
+78,257
| +738% | +$303K |
2025 Q1
1 quarter
|
|
2817
Virginia National Bankshares
VABK
$263M
| $514K | ﹤0.01% |
13,900
+100
| +0.7% | +$3.67K |
2023 Q4
6 quarters
|
|
2818
Capital Group Core Equity ETF
CGUS
$12.2B
| $513K | ﹤0.01% |
+13,900
| New | +$473K |
2025 Q2
0 quarters
|
|
2819
Vanguard S&P 500 ETF
VOO
$1.06T
| $511K | ﹤0.01% |
900
-6,100
| -87% | -$3.21M |
2024 Q3
3 quarters
|
|
2820
Imunon
IMNN
$6.06M
| $510K | ﹤0.01% |
48,913
+48,112
| +6,006% | +$657K |
2021 Q4
14 quarters
|
|
2821
iShares Core 80/20 Aggressive Allocation ETF
AOA
$3.34B
| $509K | ﹤0.01% |
6,100
+3,000
| +97% | +$235K |
2023 Q4
6 quarters
|
|
2822
Cadiz
CDZI
$290M
| $508K | ﹤0.01% |
170,000
-176,900
| -51% | -$508K |
2024 Q4
2 quarters
|
|
2823
Twist Bioscience
TWST
$10.6B
| $508K | ﹤0.01% |
13,800
-180,108
| -93% | -$6.22M |
2024 Q3
3 quarters
|
|
2824
Lifetime Brands
LCUT
$219M
| $507K | ﹤0.01% |
99,451
-400
| -0.4% | -$1.49K |
2013 Q4
46 quarters
|
|
|
BRAG
2825
Bragg Gaming Group
BRAG
$36M
| $506K | ﹤0.01% |
117,100
+20,100
| +21% | +$83.3K |
2023 Q2
8 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.